Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Equity Income (2021 - 2023)

Historic Equity Income for Intellia Therapeutics (NTLA) over the last 3 years, with Q4 2023 value amounting to -$4.7 million.

  • Intellia Therapeutics' Equity Income fell 4556.65% to -$4.7 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$4.7 million, marking a year-over-year increase of 6659.37%. This contributed to the annual value of -$15.6 million for FY2023, which is 4110.48% down from last year.
  • According to the latest figures from Q4 2023, Intellia Therapeutics' Equity Income is -$4.7 million, which was down 4556.65% from -$3.9 million recorded in Q3 2023.
  • In the past 5 years, Intellia Therapeutics' Equity Income ranged from a high of -$1.3 million in Q4 2021 and a low of -$4.7 million during Q4 2023
  • Its 3-year average for Equity Income is -$3.1 million, with a median of -$3.2 million in 2022.
  • As far as peak fluctuations go, Intellia Therapeutics' Equity Income crashed by 14513.21% in 2022, and later crashed by 1103.83% in 2023.
  • Over the past 3 years, Intellia Therapeutics' Equity Income (Quarter) stood at -$1.3 million in 2021, then tumbled by 145.13% to -$3.2 million in 2022, then tumbled by 45.57% to -$4.7 million in 2023.
  • Its Equity Income stands at -$4.7 million for Q4 2023, versus -$3.9 million for Q3 2023 and -$4.0 million for Q2 2023.